Indication
Age-related Macular Degeneration
50 clinical trials
45 products
1 drug
Product
Eyp-1901Product
AfliberceptClinical trial
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMDStatus: Active (not recruiting), Estimated PCD: 2023-11-07
Clinical trial
EXPLORE: A Phase II, Outcomes Assessor-masked, Multicentre, Randomised Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2024-03-29
Product
GT005Product
ALK-001Clinical trial
A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2023-07-25
Product
PlaceboClinical trial
A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)Status: Terminated, Estimated PCD: 2021-06-02
Product
KSI-301Clinical trial
HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMDStatus: Active (not recruiting), Estimated PCD: 2024-06-28
Product
ZimuraProduct
LucentisClinical trial
A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular DegenerationStatus: Completed, Estimated PCD: 2018-10-18
Clinical trial
A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of QA102 in Subjects With Dry Age-Related Macular Degeneration (AMD)Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
QA102/PlaceboProduct
QA102Clinical trial
A Randomized, Double-blind, Two-group Parallel, Positive-controlled Clinical Phase I Trial Comparing the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of CMAB818 and Lucentis® in Patients With Wet Age-related Macular Degeneration.Status: Completed, Estimated PCD: 2022-12-22
Product
Lucentis®Product
CMAB818Clinical trial
A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered Via Subretinal Delivery in Participants With Neovascular Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2023-10-02
Product
RGX-314Product
BAT5906Clinical trial
Phase II Clinical Study on the Efficacy and Safety of BAT5906 Injection in the Vitreous Age-related Macular Degeneration Patients With Two Repeated Intravitreal DoseStatus: Completed, Estimated PCD: 2022-09-06
Clinical trial
A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)Status: Recruiting, Estimated PCD: 2031-03-01
Product
SKG0106Clinical trial
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)Status: Recruiting, Estimated PCD: 2025-05-01
Product
RanibizumabClinical trial
A Phase 3, Randomized, Double-masked, Active Controlled Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection With Ranibizumab in Subjects With Wet Age-related Macular Degeneration (wAMD)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
ranibizumabProduct
HLX04-OClinical trial
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active Comparator Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular DegenerationStatus: Recruiting, Estimated PCD: 2027-02-25
Clinical trial
An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular DegenerationStatus: Completed, Estimated PCD: 2022-06-22
Product
ADVM-022Clinical trial
A Phase I Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular DegenerationStatus: Terminated, Estimated PCD: 2022-08-26
Product
KHK4951Clinical trial
Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical PracticeStatus: Completed, Estimated PCD: 2022-11-25
Product
RTH258/BrolucizumabClinical trial
A One-year, Single-arm, Open-label, Multicenter Study Assessing the Anatomic Outcomes of Brolucizumab Assessed by OCT-A in Adult Patients With Neovascular Age Related Macular DegenerationStatus: Completed, Estimated PCD: 2022-05-23
Clinical trial
A Long-term Study of ADVM-022 in Neovascular (Wet) AMD - OPTIC ExtensionStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Evaluation of an eXtended and proacTive Dosing regimEn in Treatment-Naïve Patients With Wet Age-related Macular Degeneration (wAMD)Status: Completed, Estimated PCD: 2023-07-07
Product
TinlarebantClinical trial
A Phase 1b, Open-Label, Parallel Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Tinlarebant in Healthy Volunteers Aged 50-85Status: Completed, Estimated PCD: 2023-01-04
Clinical trial
A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)Status: Completed, Estimated PCD: 2019-11-24
Clinical trial
A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea® in Subjects With Neovascular Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2022-09-08
Product
RPESC-RPE-4WClinical trial
A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® MonotherapyStatus: Completed, Estimated PCD: 2021-11-19
Clinical trial
A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)Status: Recruiting, Estimated PCD: 2025-05-31
Product
RBM-007Clinical trial
A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept With Proactive Customized Treatment Intervals in Patients ≥50 Years of Age With No Fluid Due to Choroidal Neovascularization (CNV) Lesions Secondary to Neovascular (Wet) Age-related Macular Degeneration (nAMD) Following Treatment Initiation With AfliberceptStatus: Terminated, Estimated PCD: 2023-07-11
Clinical trial
A Phase III, Multicenter, Randomized, Double-Masked, Parallel Controlled, Non Inferior Study to Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection With Ranibizumab in Subjects With Wet Age-related Macular Degeneration (wAMD)Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2021-11-19
Product
SCT510AClinical trial
A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103Status: Terminated, Estimated PCD: 2022-02-18
Product
GEM103Clinical trial
A Multicenter, Randomized, Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of BAT5906 and Ranibizumab (Lucentis®) in Patients With Neovascular Age-related Macular DegenerationStatus: Recruiting, Estimated PCD: 2024-06-30
Product
SCD411Product
ShamClinical trial
A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) EYE103 in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)Status: Recruiting, Estimated PCD: 2024-12-31
Product
PEGCETACOPLANClinical trial
A Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RC28-E 2mg Versus Aflibercept in Subjects With Wet Age-Related Macular DegenerationStatus: Recruiting, Estimated PCD: 2025-11-29
Product
EYE103Clinical trial
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Product
RC28-EClinical trial
A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2022-07-18
Product
ABP 938Clinical trial
A Phase I/II, Single-arm, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of HLX04-O Administered by Intravitreal Injection in Subjects With Wet Age Related Macular Degeneration (wAMD)Status: Completed, Estimated PCD: 2022-07-07
Clinical trial
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMDStatus: Recruiting, Estimated PCD: 2025-02-01
Product
EYP-1901Clinical trial
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMDStatus: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From RetinopathyStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Product
CD34+ Bone Marrow Stem CellsClinical trial
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort StudyStatus: Recruiting, Estimated PCD: 2025-12-01
Product
AspirinProduct
ClopidogrelProduct
N-acetylcysteineClinical trial
Evaluation of Efficacy of Intravitreal Bevacizumab RetreatmentsStatus: Terminated, Estimated PCD: 2006-05-01
Product
BevacizumabClinical trial
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)Status: Completed, Estimated PCD: 2023-03-28
Clinical trial
Effects of Intravitreal Injection of Bevacizumab in Combination With Verteporfin Photodynamic TherapyStatus: Terminated, Estimated PCD: 2006-06-30
Clinical trial
Effect of Oral Curcumin Supplementation on Choriocapillaris and Drusen Characteristics Measured by Multimodal Retinal Imaging in Dry Age-related Macular Degeneration (AMD) PatientsStatus: Completed, Estimated PCD: 2023-06-01
Product
Longvida curcuminClinical trial
MMP-9 Inhibition for Recalcitrant Wet Age-Related Macular Degeneration (AMD)Status: Recruiting, Estimated PCD: 2023-12-31
Product
Doxycycline HyclateDrug
VarlilumabClinical trial
Evaluation of RBM-007 in Subjects With Treatment naïve Exudative Age-related Macular Degeneration (AMD)Status: Completed, Estimated PCD: 2022-02-08
Clinical trial
Study Comparing Early Extension of Aflibercept and Brolucizumab in Wet AMD (SPARROW)Status: , Estimated PCD: 2027-06-01
Product
BrolucizumabClinical trial
Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration: A Pilot StudyStatus: Terminated, Estimated PCD: 2006-06-01
Product
bevacizumabClinical trial
The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
metagenomeClinical trial
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic AtrophyStatus: Recruiting, Estimated PCD: 2025-10-07
Product
Dimethyl Fumarate